Excessive (qualifier value)
FDA Approves Avadel’s Lumryz for Pediatric Narcolepsy Patients
Avadel Pharmaceuticals, Lumryz, narcolepsy, pediatric patients, FDA approval, sodium oxybate, cataplexy, excessive daytime sleepiness (EDS)
Actionable Insights Powered by AI
Avadel Pharmaceuticals, Lumryz, narcolepsy, pediatric patients, FDA approval, sodium oxybate, cataplexy, excessive daytime sleepiness (EDS)